Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox-A for Low Anterior Resection Syndrome
NCT01589471Phase 2Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- May 2012
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in low anterior resection syndrome (LARS), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Anorectal function assessed by Wexner score at 3 months. Started May 2012; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on NCT01589471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01589471.